Increased Risk of Pneumocystis Jiroveci Pneumonia Among Patients with Inflammatory Bowel Disease | Zendy

Millie D. Long | Zendy; Francis A. Farraye | Zendy; Philip N. Okafor | Zendy; Christopher Martin | Zendy; Robert S. Sandler | Zendy; Michael D. Kappelman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Increased Risk of Pneumocystis Jiroveci Pneumonia Among Patients with Inflammatory Bowel Disease

Author(s) -

Millie D. Long,

Francis A. Farraye,

Philip N. Okafor,

Christopher Martin,

Robert S. Sandler,

Michael D. Kappelman

Publication year - 2013

Publication title -

inflammatory bowel diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.932

H-Index - 146

eISSN - 1536-4844

pISSN - 1078-0998

DOI - 10.1097/mib.0b013e3182802a9b

Subject(s) - medicine , inflammatory bowel disease , hazard ratio , ulcerative colitis , cohort , incidence (geometry) , interquartile range , retrospective cohort study , cohort study , crohn's disease , proportional hazards model , rate ratio , relative risk , confidence interval , gastroenterology , disease , physics , optics

Patients with inflammatory bowel disease (IBD) may be at increased risk for pneumocystis jiroveci pneumonia (PCP). Our aims were (1) to determine the incidence and relative risk of PCP in IBD and (2) to describe medication exposures in patients with IBD with PCP.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research